Bloomberg Podcasts
@bloombergpodcasts·503K subscribers·32.4K videos
Closing Bell: Broadcom Rallies, Sable Offshore Higher, Roche Slumps | Stock Movers
Posted
March 5, 2026
Views
200
Likes
4
Engagement
2.00%
March 5, 2026
200
4
2.00%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
7:16Now PlayingToday's biggest winners and losers in the stock market.
On this episode of Stock Movers:
Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Katie Greifeld, Carol Massar and Tim Stenovec.
- Broadcom (AVGO)'s CEO Hock Tan said the company expects its AI chip sales to top $100 billion next year, marking major inroads into territory dominated by Nvidia. “We have line of sight” to reach this milestone in 2027, he said during a conference call with analysts Wednesday. “We have also secured the supply chain required to achieve this.” Broadcom shares rose as much as 4.2% on Thursday after trading got underway in New York.
- Sable Offshore (SOC) saw its shares trade higher on word the US is considering using the emergency powers of a Cold War-era law to ease permitting for it’s contested plans to drill oil off the coast of California. The 1950s Defense Production Act, which gives the president broad powers over domestic industry, is “absolutely” under deliberation to help Sable, US Interior Secretary Doug Burgum said Thursday in an interview. Shares rose 12% on the news and are up more than 60% this week as investors positioned ahead of a possible move by the Trump administration.
- Roche (RHHBY) and Zealand Pharma (ZEAL)'s experimental obesity shot helped patients lose as much as 10.7% in a study, failing to clear a high bar set by some Wall Street analysts. The experimental shot, petrelintide, delivered weight loss with side effects comparable to placebo, with fewer than 5% of patients dropping out of the trial, Roche and Zealand said. The results came after 42 weeks of treatment. Roche’s American depositary receipts fell as much as 7% after the results were posted Thursday.
See omnystudio.com/listener () for privacy information.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.
Check out more episodes of Stock Movers
Follow Bloomberg Podcasts on Twitter
Visit our other YouTube channels:
Bloomberg Television
Bloomberg Originals
For coverage on news, markets and more
#Stocks #Markets #Finance #Investing #Podcast #Bloomberg
Closing Bell: Broadcom Rallies, Sable Offshore Higher, Roche Slumps
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
